Key Events This Week
15 Sep: Intraday low amid heavy price pressure (Rs.2,209.6)
16 Sep: Further intraday low despite Sensex gains (Rs.1,992.8)
17 Sep: Intraday high and upper circuit hit (Rs.2,116.6 / Rs.2,118.40)
18 Sep: Week closes lower at Rs.2,057.50 (-1.12%)
15 September 2026: Intraday Low Amid Price Pressure
Novartis India Ltd opened the week under significant selling pressure, with its share price falling 8.51% to close at Rs.2,189.55. The stock hit an intraday low of Rs.2,209.6, marking a 7.67% drop from the previous close. This decline was sharper than the Sensex’s 1.69% fall to 35,169.62, indicating company-specific weakness amid a cautious market mood. Despite the sharp intraday fall, the stock remained above key moving averages, suggesting that longer-term technical support was still intact. However, the immediate selling pressure outweighed these supports, reflecting a challenging trading session.
16 September 2026: Continued Decline Despite Market Gains
The downward momentum persisted on 16 September, with Novartis India Ltd’s stock price dropping a further 8.80% to Rs.1,996.85, touching an intraday low of Rs.1,992.8. This decline occurred despite the Sensex gaining 0.30% to close at 35,276.25, underscoring company-specific pressures. The stock’s three-day losing streak culminated in a cumulative 16.42% loss. Technical indicators showed the price trading below its 5-day moving average, signalling short-term weakness, although longer-term averages remained supportive. The Pharmaceuticals & Biotechnology sector also underperformed, but Novartis India Ltd’s losses exceeded sector declines, highlighting intensified selling pressure on the stock.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
17 September 2026: Strong Rebound and Upper Circuit Surge
After three consecutive days of decline, Novartis India Ltd staged a notable recovery on 17 September, surging 4.21% to close at Rs.2,080.85. Intraday, the stock hit a high of Rs.2,116.6, a 7.55% increase from the previous close, and later surged to the upper circuit limit of 6.16%, closing at Rs.2,118.40. This rally was driven by robust buying interest, with the stock outperforming its Pharmaceuticals & Biotechnology sector by 6.21% and the Sensex by 4.15%. The surge was accompanied by a regulatory freeze on further buying due to the upper circuit hit, indicating strong demand. Despite the volatility, the stock remained above its medium- and long-term moving averages, signalling sustained underlying strength.
18 September 2026: Week Ends with Mild Decline
The final trading day saw a modest pullback, with Novartis India Ltd closing at Rs.2,057.50, down 1.12% from the previous close. The Sensex continued its positive trend, gaining 0.52% to 35,625.23. The stock’s volume declined to 8,249 shares, reflecting reduced investor participation after the prior day’s surge. The week’s overall performance, however, remained negative with a 14.03% loss from the previous Friday’s close of Rs.2,393.15, significantly underperforming the Sensex’s 0.41% decline. This final session suggested some consolidation following the sharp rebound on 17 September.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-15 | Rs.2,189.55 | -8.51% | 35,169.62 | -1.69% |
| 2026-09-16 | Rs.1,996.85 | -8.80% | 35,276.25 | +0.30% |
| 2026-09-17 | Rs.2,080.85 | +4.21% | 35,439.31 | +0.46% |
| 2026-09-18 | Rs.2,057.50 | -1.12% | 35,625.23 | +0.52% |
Novartis India Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this small-cap stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth small-cap analysis
- - Valuation assessment included
Key Takeaways from the Week
Volatility and Price Pressure: The week was characterised by sharp intraday declines on 15 and 16 September, with the stock losing over 16% in three days. This was despite the Sensex showing resilience on 16 September, highlighting company-specific selling pressure likely driven by profit-taking and short-term technical adjustments.
Strong Rebound and Upper Circuit: The 7.55% intraday surge and upper circuit hit on 17 September demonstrated renewed buying interest and a potential shift in momentum. The regulatory freeze on further buying underscored robust demand, although delivery volumes were subdued, suggesting cautious accumulation.
Technical Indicators: Despite short-term weakness, the stock remained above its 20-day and longer moving averages, supported by bullish weekly and monthly MACD and Bollinger Bands. Mixed signals from RSI and KST indicators suggest some caution in momentum, but the overall medium- to long-term trend remains positive.
Relative Performance: Novartis India Ltd underperformed the Sensex by a wide margin, falling 14.03% versus the index’s 0.41% decline. However, the stock’s longer-term returns remain impressive, with year-to-date gains exceeding 175%, far outpacing the broader market.
Conclusion
Novartis India Ltd’s week was marked by significant volatility and a steep price correction, reflecting short-term profit-taking and market caution. The sharp declines on 15 and 16 September contrasted with a strong rebound and upper circuit surge on 17 September, signalling a complex trading environment. While the stock closed the week lower by 14.03%, technical indicators and a recent upgrade to a Buy mojo grade suggest underlying resilience. Investors should note the divergence between short-term price pressure and longer-term strength, with the stock’s performance continuing to stand out within the Pharmaceuticals & Biotechnology sector despite recent setbacks.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
